AI-generated analysis. Always verify with the original filing.
Alnylam Pharmaceuticals reported fourth quarter and full year 2025 financial results, achieving global net product revenues of $995 million for Q4 and $2,987 million for the full year, representing 121% and 81% growth compared to 2024, respectively, and attaining GAAP and non-GAAP profitability for the full year. The company also launched its 'Alnylam 2030' strategy and provided 2026 financial guidance.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan
. Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release
| Metric | Value | Basis |
|---|---|---|
| Total Revenues | $1.1M | |
| GAAP Income from Operations | $131.7K | GAAP |
| Non-GAAP Income from Operations | $203.3K | Non-GAAP |
| GAAP Net Income | $111.5K | GAAP |
| Non-GAAP Net Income | $169.8K | Non-GAAP |
| GAAP Diluted EPS | $0.82 | GAAP |
| Non-GAAP Diluted EPS | $1.25 | Non-GAAP |
| Net Product Revenues | $994.7K |
Net Product Sales Guidance
Reiterated
Additional Financial Guidance
Provided